Scarica l'app Stockscreener
37.24
5.79%
-2.29
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$39.53
Aprire:
$38.68
Volume 24 ore:
1.20M
Relative Volume:
0.37
Capitalizzazione di mercato:
$5.72B
Reddito:
-
Utile/perdita netta:
$-284.08M
Rapporto P/E:
-15.37
EPS:
-2.4234
Flusso di cassa netto:
$-234.65M
1 W Prestazione:
-4.37%
1M Prestazione:
-7.29%
6M Prestazione:
+201.05%
1 anno Prestazione:
+318.90%
Intervallo 1D:
$37.00
$38.93
Intervallo di 1 settimana:
$37.00
$40.40
Portata 52W:
$3.72
$43.73
Cogent Biosciences Inc Stock (COGT) Company Profile
Nome
Cogent Biosciences Inc
Settore
Industria
Telefono
617-945-5576
Indirizzo
275 WYMAN STREET, WALTHAM
Confronta COGT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
COGT
Cogent Biosciences Inc
|
37.23 | 6.07B | 0 | -284.08M | -234.65M | -2.4234 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.63 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.34 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.84 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Cogent Biosciences Inc Stock (COGT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-10 | Aggiornamento | Stifel | Hold → Buy |
| 2025-11-10 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2025-10-16 | Iniziato | Stifel | Hold |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-03-07 | Iniziato | Scotiabank | Sector Outperform |
| 2024-12-11 | Downgrade | Needham | Buy → Hold |
| 2024-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-02-08 | Iniziato | Citigroup | Buy |
| 2023-12-11 | Downgrade | Wedbush | Outperform → Neutral |
| 2023-12-08 | Iniziato | JP Morgan | Overweight |
| 2023-04-28 | Iniziato | Robert W. Baird | Outperform |
| 2023-03-27 | Ripresa | H.C. Wainwright | Buy |
| 2022-12-14 | Iniziato | Needham | Buy |
| 2022-06-28 | Iniziato | Guggenheim | Buy |
| 2021-10-11 | Iniziato | H.C. Wainwright | Buy |
| 2021-06-09 | Ripresa | Jefferies | Buy |
| 2020-12-23 | Iniziato | Piper Sandler | Overweight |
| 2020-10-14 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Cogent Biosciences Inc Borsa (COGT) Ultime notizie
Emerald Mutual Fund Advisers Trust Grows Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (NASDAQ:COGT) Director Fairmount Funds Management Llc Sells 3,500,000 Shares - MarketBeat
Fairmount funds sells Cogent Biosciences (COGT) shares worth $127.4 million - Investing.com Canada
Emerald Advisers LLC Increases Stock Position in Cogent Biosciences, Inc. $COGT - MarketBeat
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib ComboHas The Bull Case Changed? - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Earns Outperform Rating from Wedbush - MarketBeat
Wedbush Reiterates "Outperform" Rating for Cogent Biosciences (C - GuruFocus
Cogent Biosciences Initiates New Drug Application Submission for Bezuclastinib Under Real-Time Oncology Review - marketscreener.com
FDA Greenlights Cogent Biosciences' New Drug Application for GIS - GuruFocus
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR) - The Manila Times
Cancer drug combo cuts GIST progression risk by 50% in key trial - Stock Titan
Campbell & CO Investment Adviser LLC Purchases Shares of 61,634 Cogent Biosciences, Inc. $COGT - MarketBeat
What makes Cogent Biosciences Inc. stock attractive todayQuarterly Profit Review & Expert Verified Movement Alerts - bollywoodhelpline.com
HC Wainwright is bullish on Cogent Biosciences, Inc. (COGT) - MSN
Geopolitics Watch: What are Cogent Biosciences Incs recent SEC filings showingShort Setup & Risk Managed Investment Entry Signals - baoquankhu1.vn
Why Cogent Biosciences (COGT) Is Up 10.3% After Mapping Bezuclastinib’s Multi-Indication NDA Strategy - Sahm
(COGT) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Assessing Cogent Biosciences (COGT) Valuation After Bezuclastinib FDA NDA Submission - Sahm
Cogent Biosciences (COGT) stock jumps as FDA filing timeline sharpens — what investors watch next - TechStock²
Cogent Biosciences (NASDAQ:COGT) Shares Up 7.1%Still a Buy? - MarketBeat
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio - Investing News Network
Cogent Biosciences (COGT) Soars 126% on Stomach Cancer Treatment Progress - MSN
Cogent Biosciences Announces Anticipated 2026 Commercial - GlobeNewswire
Cancer drug maker lays out 2026 plans for new treatments and trials - Stock Titan
H.C. Wainwright is Bullish on Cogent Biosciences, Inc. (COGT) - Finviz
Cogent Insider Sells $2.5 Million in Stock Amid Staggering 300% Price Surge - The Motley Fool
Cogent Biosciences announces proposed concurrent public offerings - MSN
Cogent Biosciences Inc. (COGT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is Cogent Biosciences Inc. stock a buy for dividend growthDurability and Wear Notes & lightweight options for faster days - ulpravda.ru
Cogent Biosciences, Inc. (COGT) Stock Analysis: Unlocking A 41% Upside Potential - DirectorsTalk Interviews
Cogent Bio surges after late-stage trial data for lead drug - MSN
A Look At Cogent Biosciences (COGT) Valuation After Positive Bezuclastinib NDA Filing - Yahoo Finance
Cogent Biosciences (NASDAQ:COGT) Stock Rating Upgraded by UBS Group - MarketBeat
Aug Ideas: Is Cogent Biosciences Inc. stock a buy for dividend growth2025 Macro Impact & Weekly Chart Analysis and Trade Guides - ulpravda.ru
Will Cogent Biosciences Inc. stock split again soon2025 Volume Leaders & Reliable Price Breakout Signals - ulpravda.ru
Will Cogent Biosciences Inc. stock deliver long term returnsWeekly Profit Summary & Community Consensus Trade Signals - ulpravda.ru
Why Cogent Biosciences Inc. stock is in analyst buy zone2025 EndofYear Setup & Free Technical Confirmation Trade Alerts - ulpravda.ru
Will Cogent Biosciences Inc. stock outperform growth indexesQuarterly Growth Report & Precise Entry and Exit Recommendations - Улправда
How Cogent Biosciences Inc. stock performs during Fed tightening cyclesMarket Movers & Safe Entry Point Identification - ulpravda.ru
Will Cogent Biosciences Inc. stock attract more institutional investorsJuly 2025 Sentiment & Verified Entry Point Detection - ulpravda.ru
Does Cogent Biosciences Inc. stock trade at a discount to peersJuly 2025 Market Mood & Smart Swing Trading Alerts - ulpravda.ru
Cogent Biosciences price target raised to $52 from $50 at HC Wainwright - MSN
Does Cogent Biosciences (COGT) Bezuclastinib NDA Redefine Its Competitive Position in Mastocytosis Treatment? - Sahm
Cogent Biosciences announces presentation at the 44th annual J.P. Morgan Healthcare conference - marketscreener.com
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Cogent Biosciences, Inc. CEO Andrew Robbins to Present at 44th Annual J.P. Morgan Healthcare Conference - Quiver Quantitative
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COG - GuruFocus
COGT Gets a Boost: HC Wainwright & Co. Raises Target Price | COGT Stock News - GuruFocus
Liquidity Mapping Around (COGT) Price Events - Stock Traders Daily
Cogent Biosciences down after market close on insider sales - MSN
Best Biotech Stocks To Follow TodayDecember 31st - MarketBeat
Cogent Biosciences Inc Azioni (COGT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):